Johnson & Johnson’s blockbuster psoriasis drug, Stelara, showed promising results in a midstage clinical trial of patients with systemic lupus.
Janssen Biotech already has FDA approval for Sterlara for psoriasis (2009), psoriatic arthritis (2013) and Crohn’s disease (2016).
In the current trial of 102 patients with active lupus on standard therapy, 60 percent of those who received Stelara experienced improvement after 24 weeks of treatment. According to J&J, these results are strong enough to advance Stelara into larger Phase III testing.
Read the Reuters coverage